Ovid Therapeutics, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,

A letter to US Senate Health, Education, Labor and Pensions (HELP) committee chairman Bill Cassidy, R-LA, from more than 200 biotech leaders, investors and patient advocates cites cases of disruptions

Included for 2025 are investors, CEOs of small and mid-sized companies, rising employees in larger businesses, and individuals spearheading unique health initiatives worldwide. The 30 individuals list

Looking ahead to 2025, industry leaders shared their insights into the key trends and topics they expect to see. Click on topic headings to read executive predictions. The insights in this article hav